Improving care for neonatal abstinence syndrome

Pediatrics

Volumn 137, Issue 5, 2016, Pages

  Patrick, Stephen W ^a,b,c   Schumacher, Robert E ^d   Horbar, Jeffrey D ^e,f   Buus Frank, Madge E ^e,f,g   Edwards, Erika M ^e,h   Morrow, Kate A ^e   Ferrelli, Karla R ^e   Picarillo, Alan P ^i,j   Gupta, Munish ^j,k,l   Soll, Roger F ^e,f  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e VERMONT OXFORD NETWORK   (United States)

^f Departments of Pediatrics   (United States)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h University of Vermont   (United States)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j Neonatal Quality Improvement Collaborative of Massachusetts   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CLONIDINE; METHADONE; MORPHINE; OPIATE; PAREGORIC; PHENOBARBITAL;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG WITHDRAWAL; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HOSPITAL POLICY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; NEWBORN CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; WITHDRAWAL SYNDROME; CANADA; CLINICAL AUDIT; CLINICAL PROTOCOL; CLINICAL TRIAL; HOSPITAL; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; STANDARDS; TOTAL QUALITY MANAGEMENT; UNITED KINGDOM; UNITED STATES;

CANADA; CLINICAL PROTOCOLS; HOSPITALS; HUMANS; INFANT, NEWBORN; LENGTH OF STAY; MEDICAL AUDIT; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; UNITED KINGDOM; UNITED STATES;

EID: 84969772298     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-3835     Document Type: Article

References (29)

1. Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2). Available at: www. pediatrics. org/ cgi/ content/ full/ 129/ 2/ e540
2. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934-1940
3. Epstein RA, Bobo WV, Martin PR, et al. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol. 2013;23(8):498-503
4. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaidenrolled women. Obstet Gynecol. 2014;123(5):997-1002
5. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U. S. neonatal ICUs. N Engl J Med. 2015;372(22):2118-2126
6. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012 [published correction appears in J Perinatol. 2015;35(8):667]. J Perinatol. 2015;35(8):650-655
7. Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol. 2014;34(11):867-872
8. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006;26(1):15-17
9. Horbar JD, Soll RF, Edwards WH. The Vermont Oxford Network: a community of practice. Clin Perinatol. 2010;37(1):29-47
10. Horbar JD. The Vermont Oxford Network: evidence-based quality improvement for neonatology. Pediatrics. 1999;103(1 suppl E):350-359
11. Plsek PE. Quality improvement methods in clinical medicine. Pediatrics. 1999;103(1 suppl E):203-214
12. Hall ES, Wexelblatt SL, Crowley M, et al; OCHNAS Consortium. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics. 2014;134(2). Available at: www. pediatrics. org/ cgi/ content/ full/ 134/ 2/ e527
13. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331
14. Agthe AG, Kim GR, Mathias KB, et al. CloniDine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123(5). Available at: www. pediatrics. org/ cgi/ content/ full/ 123/ 5/ e849
15. Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol. 2015;35(4):278-283
16. Hall ES, Wexelblatt SL, Crowley M, et al; OCHNAS Consortium. Implementation of a neonatal abstinence syndrome weaning protocol: a multicenter cohort study. Pediatrics. 2015;136(4). Available at: www. pediatrics. org/ cgi/ content/ full/ 136/ 4/ e803
17. Jansson LM; Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #21: Guidelines for breastfeeding and the drugdependent woman. Breastfeed Med. 2009;4(4):225-228
18. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioidexposed infants. Acta Paediatr. 2013;102(11):1060-1066
19. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med. 2010;5(4):159-164
20. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014;9(1):19
21. Prenatal Drug Use and Newborn Health. Federal Efforts Need Better Coordination and Planning. Washington, DC: United States Government Accountability Office; 2015
22. Warren MD, Miller AM, Traylor J, Bauer A, Patrick SW; Centers for Disease Control and Prevention (CDC). Implementation of a statewide surveillance system for neonatal abstinence syndrome-Tennessee, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(5):125-128
23. Lind JN, Petersen EE, Lederer PA, et al; Centers for Disease Control and Prevention (CDC). Infant and maternal characteristics in neonatal abstinence syndrome-selected hospitals in Florida, 2010-2011. MMWR Morb Mortal Wkly Rep. 2015;64(8):213-216
24. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842-850
25. Patrick SW, Davis MM. Reformulating the federal match as a key to the sustainability of Medicaid. JAMA Pediatr. 2013;167(3):218-220
26. Kellogg A, Rose CH, Harms RH, Watson WJ. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol. 2011;204(3): 259. e1-4
27. Statewide Task Force on Prescription Drug Abuse & Newborns. Available at: http:// myfl oridalegal. com/ pages. nsf/ Main/ CFC9846F8D7790FC8 5257A10004AE67E. Accessed March 2, 2015
28. Massachusetts Neonatal Abstinence Syndrome Improvement Project. Available at: www. neoqic. org/ nasproject. Accessed March 2, 2015
29. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013;309(17):1821-1827